Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.68 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.65 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.59 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27608138 | 0.86 | PARP1 (0.64) | PARP1PARP10TNKSPARP15PARP14 | |
| SCHEMBL6322882 | 0.85 | KMT2A (0.61) | PARP10MEN1KMT2AGAAHTT | |
| SCHEMBL8867012 | 0.84 | MEN1 (0.53) | PARP1PARP10MEN1KMT2AGAA | |
| SCHEMBL11798200 | 0.83 | KMT2A (0.64) | PARP1PARP10MEN1KMT2AGAA | |
| SCHEMBL104194 | 0.83 | KMT2A (0.59) | MEN1KMT2AGAAHTTRXRA | |
| SCHEMBL592781 | 0.83 | RXRA (0.68) | MEN1KMT2AGAAHTTRXRA | |
| SCHEMBL30184304 | 0.83 | RXRA (0.68) | MEN1KMT2AGAAHTTRXRA | |
| SCHEMBL28222363 | 0.83 | PARP1 (0.65) | PARP1PARP10TNKSPARP15PARP14 | |
| SCHEMBL27999431 | 0.83 | PARP1 (0.60) | PARP1PARP10TNKSPARP15PARP14 | |
| SCHEMBL1167621 | 0.81 | KMT2A (0.58) | PARP1PARP10MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023057548-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-04-13 | — | — | WO | claimed |
| CN-111601790-B | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| EP-3749646-B1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2022-04-06 | — | — | EP | claimed |
| EP-3386951-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | H. Hoffnabb-La Roche Ag (CH) | 2018-10-17 | — | — | EP | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| WO-2017097732-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-15 | — | — | WO | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| CN-102008459-B | Antibacterial agents | BIOTA SCIENT MAN | 2013-05-29 | — | — | CN | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-2188289-A2 | (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | Lexicon Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| EP-1730122-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-12-13 | — | — | EP | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2005095357-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | WO | claimed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | PARP1 4568/4885PARP10 4135/4885TNKS 4138/4885 |
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | PARP1 3297/4885PARP10 836/4885TNKS 3580/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | PARP1 4568/4885PARP10 4135/4885TNKS 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.